Business Context and Reporting Period
Company: Astro-Med, Inc. (Note: Input metadata referenced "Astronova, Inc.", but the filing text identifies the registrant as Astro-Med, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended August 4, 2001.
Business Overview: The company operates in three primary product groups: Grass-Telefactor (clinical/neurophysiology), QuickLabel Systems (QLS - specialty printers), and Test & Measurement (T&M).
Key Financial Metrics
| Metric | Three Months Ended Aug 4, 2001 |
Six Months Ended Aug 4, 2001 |
|---|---|---|
| Net Sales | $12,131,706 | $24,567,716 |
| Gross Profit | $4,765,969 | $9,818,066 |
| Gross Margin | 39.3% | 40.0% |
| Operating Income (Loss) | $(319,134) | $(302,653) |
| Net Income (Loss) | $(194,058) | $(44,394) |
| Diluted EPS | $(0.05) | $(0.01) |
| Cash from Operations | N/A (Quarterly) | $918,901 |
| Cash & Equivalents | $2,106,649 | $2,106,649 |
| Total Debt (Current) | $44,813 | $44,813 |
Liquidity: As of August 4, 2001, the company held $2.1 million in cash and cash equivalents and $4.1 million in securities available for sale. The company maintains a $2.0 million line of credit, with $3.5 million total available and unused borrowings.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9% in the quarter and 5% in the six-month period compared to the prior year. International sales dropped 14% (quarter) and 9% (six months) due to a sluggish European economy and a strong U.S. dollar.
- Profitability Shift: The company reported a net loss of $194,000 for the quarter and $44,000 for the six months, reversing to a net income of $268,000 and $426,000, respectively, in the prior year periods.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 4% in the quarter and 5% in the six months, primarily driven by higher international dealer commissions. Research and Development (R&D) spending decreased 19% in the quarter and 18% in the six months.
- Cash Flow Improvement: Net cash provided by operating activities turned positive at $919,000 for the six months ended August 4, 2001, compared to a use of $2.2 million in the prior year period.
Outlook, Risks, and Management Commentary
- Product Delays: Sales in the Test & Measurement (T&M) segment were negatively impacted by delays in delivering the new "Dash 18" product. Inventory levels increased in anticipation of this launch and other product lines (Pronto), causing inventory turns to decline from 2.5 to 2.0.
- Customer Spending: QLS sales declined as customers delayed capital spending on hardware.
- Legal Settlement: Other income for the six-month period included a $125,000 gain from the settlement of litigation regarding a contract dispute.
- Risks: Management cites risks including declining demand in defense and aerospace markets, competition in specialty printers and data acquisition, foreign currency exchange rate fluctuations, and the ability to integrate acquisitions.
- Accounting Changes: The company adopted SFAS No. 133 (Derivatives) with no material impact. It plans to adopt SFAS No. 141 and 142 (Business Combinations and Goodwill) effective January 31, 2002, which will cease goodwill amortization.
Investor Verification Checklist
- Product Launch Timeline: Verify the status and expected revenue impact of the delayed "Dash 18" product line.
- Inventory Valuation: Assess the risk of inventory write-downs given the increase in inventory levels and the decline in inventory turns to 2.0.
- International Exposure: Monitor the impact of the strong U.S. dollar and European economic conditions on future international sales.
- Capital Expenditures: Review the return on the 42% increase in capital expenditures ($564,000) intended to improve manufacturing processes.
- Debt Covenants: Confirm the terms and utilization of the new $2.0 million line of credit and any associated covenants.